P278 Transcranial direct current stimulation (tDCS) as treatment for major depression (DepressionDC) – Objectives and design of a prospective multicenter double blind randomized placebo controlled trial

2017 ◽  
Vol 128 (3) ◽  
pp. e146-e147
Author(s):  
U. Kumpf ◽  
U. Palm ◽  
J. Nolden ◽  
A. Pfeiffer ◽  
S. Egert ◽  
...  
Keyword(s):  
Major Depression ◽  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Controlled Trial ◽  
Double Blind ◽  
Direct Current Stimulation

Transcranial Direct Current Stimulation for Treatment-Resistant Major Depression: A Double-Blind Randomized Sham-Controlled Trial

2019 ◽  
Vol 50 (6) ◽  
pp. 375-382 ◽  
Author(s):  
Elham Sharafi ◽  
Arsia Taghva ◽  
Mohammad Arbabi ◽  
Afsaneh Dadarkhah ◽  
Jamshid Ghaderi
Keyword(s):  
Major Depression ◽  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Controlled Trial ◽  
Active Group ◽  
Treatment Resistant ◽  
Double Blind ◽  
Direct Current Stimulation ◽  
Significant Difference ◽  
The Mean

In the current study, we tried to evaluate the effect of transcranial direct current stimulation (tDCS) on treatment-resistant major depression. We carried out a double-blind randomized sham-controlled trial was conducted in University Hospitals. Individuals with less than 50% decrease in the intensity of depression after 8 weeks of treatment with selective serotonin reuptake inhibitors were recruited. Thirty patients (16 women) with a mean (SD) age of 47.2 (12.0) years were randomly allocated to 2 groups. For the active group we administered 2-mA stimulation 20 minutes for each session, with 30 seconds ramp-up from 0 and 30 seconds ramp-down. For the sham group we administered 30 seconds ramp-up to 2 mA, 10 seconds stimulation, 30 seconds ramp-down, and 20 minutes no current. The anode was fixed on the center of F3, and the cathode on F4, over the dorsolateral prefrontal cortex. We assessed the Hamilton Depression Rating Scale at the baseline (mean difference = 1.0, P = .630), at the last session of tDCS, and at 1-month postintervention. There were statistically significant differences in the mean Hamilton scores after the intervention, and 1 month later in favor of active group; P < .001, and P = .003, respectively. Mixed analysis of variance showed a significant difference in the mean scores for active group P = .010 and pattern of change during the study P < .001 in favor of active intervention. We concluded that tDCS is an efficient therapy for patients with resistant major depression, and the benefits would remain at least for 1 month.

scholarly journals Transcranial direct current stimulation in management of pain, mood, functionality, and quality of life in patients undergoing hemodialysis: a study protocol for a double-blind controlled randomized trial

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Artur Quintiliano ◽  
Tayanne Oehmen ◽  
Gianna Mastroianni Kirsztajn ◽  
Rodrigo Pegado
Keyword(s):  
Quality Of Life ◽  
Chronic Pain ◽  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Pharmacological Treatment ◽  
Controlled Trial ◽  
Double Blind ◽  
Direct Current Stimulation ◽  
Continuous Current

Abstract Background Persistent pain can lead to incapacitation requiring long-term pharmacological treatment. Up to 82% of chronic kidney disease (CKD) patients undergoing hemodialysis (HD) have chronic pain and most do not respond to usual medication. Advances in non-pharmacological treatments are necessary to promote pain relief without side effects and to restore functionality. Transcranial direct current stimulation (tDCS) promises to be a novel, cost-efficient, non-pharmacological treatment for CKD patients with chronic pain. In this study, we hypothesize that tDCS could improve pain, depression, functionality, and quality of life in patients with CKD undergoing HD. Methods/design We describe a single-center, parallel-design, double blind randomized, sham-controlled trial. Forty-five subjects with CKD undergoing HD will be randomized to a motor cortex (M1), a dorso lateral prefrontal cortex (DLPFC), or a sham group. A total of ten sessions will be administered to participants over 4 weeks using a monophasic continuous current with an intensity of 2 mA for 20 min. Participants will be evaluated at baseline, immediately after the tenth session, and at 1 week and 4 weeks of follow-up after the intervention. Pain, depression, functionality, and quality of life will be evaluated. Discussion The results from this study will provide initial clinical evidence on the efficacy and safety of tDCS in patients with CKD undergoing HD. Trial registration Brazilian Clinical Trials Registry/Registro Brasileiro de Ensaios Clínicos (ensaiosclinicos.gov.br), 1111–1216-0137. Registered on 20 June 2018.

Sign in / Sign up

Export Citation Format

Share Document